Dental Care Clinics in Dumas, TX Accepting Medicare
9 Dental Care Clinics found. Showing 1 - 9
 Dumas Family Dentistry Clinic/Center - Dental Medicare: Not Enrolled in Medicare Practice Location: 1401 E 1st St, Dumas, TX 79029 Phone: 806-935-2725 Fax: 806-935-2680 |
Casa Dental-dumas Pllc Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 2100 S Dumas Ave Ste 112, Dumas, TX 79029 Phone: 806-934-3170 Fax: 806-934-3172 |
David M. Bonner, D.d.s., P.c. Dentist Medicare: Not Enrolled in Medicare Practice Location: 101 Binkley, Dumas, TX 79029 Phone: 806-935-6811 Fax: 806-935-9080 |
Bumble Bee Smiles Dentist - Pediatric Dentistry Medicare: Not Enrolled in Medicare Practice Location: 115 W. First St., Dumas, TX 79029 Phone: 806-355-9732 Fax: 806-329-0244 |
Bonner Family Dentistry, Pllc Dentist Medicare: Not Enrolled in Medicare Practice Location: 404 E 1st St, Dumas, TX 79029 Phone: 806-935-6811 Fax: 806-935-9080 |
Aoms Dental Group, Pllc Dentist Medicare: Not Enrolled in Medicare Practice Location: 315 E 2nd St, Dumas, TX 79029 Phone: 806-353-1055 |
Casa Dental Dentist Medicare: Not Enrolled in Medicare Practice Location: 2100 South Dumas Ave, Ste 112, Dumas, TX 79029 Phone: 617-281-7947 |
Casa Dental Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 2100 S Dumas Ave Ste 112, Dumas, TX 79029 Phone: 806-934-3170 |
Dumas Family Dental Care Pllc Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 404 E. 1st St, Dumas, TX 79029 Phone: 806-935-6811 |
News Archive
Chronic fatigue syndrome may be reason behind many school absenteeism: Study
According to a new study one in 100 secondary school pupils could be missing classes because of chronic fatigue syndrome, also known as Myalgic Encephalomyelitis (ME). A study following 2,855 pupils at three schools, published in the online journal BMJ Open, found 28 missed school with chronic fatigue syndrome.
Kiadis Pharma receives FDA approval for IND to start pivotal clinical study for ATIR
Biopharmaceutical Company Kiadis Pharma announced today that it has received approval for its Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) to start the pivotal clinical study for its product ATIR™ in the United States. Kiadis Pharma is currently enrolling patients in a multinational, pivotal clinical study at hospitals in Europe and Canada. With the approval of the IND, US hospitals will also participate in this study.
Jubilant Organosys, UAB and Southern Research Institute announce joint venture to accelerate global drug development
Jubilant Organosys, the University of Alabama at Birmingham (UAB), and Southern Research Institute today announced a joint venture that will focus on leveraging their collective innovation and enabling technologies in the areas of Oncology, Metabolic Disease and Infectious Diseases. It is a unique U.S.-India arbitraged and leveraged partnership that will accelerate the development of affordable therapies for patients worldwide.
New application note describes ChIP assay technology for screening multiple epigenetic targets
Porvair Sciences has announced an application note describing the excellent results achievable from a new 96-well format version of its ChromaTrap chromatin immunoprecipitation assay technology.
Afinitor-Sandostatin LAR Depot combination extends median PFS in patients with advanced carcinoid tumors
A Novartis Pharmaceuticals Corporation Phase III study of Afinitor® (everolimus) tablets in combination with Sandostatin® LAR Depot (octreotide acetate for injectable suspension) extended median progression-free survival (PFS), or time without tumor growth, in patients with advanced carcinoid tumors compared to taking octreotide LAR alone.
› Verified 1 days ago